Timing, hosts and locations of (grouped) events of NanoImpactNet

More documents

Recommendations

Info

NanoSafetyCluster - Compendium 2012 antibody-opsonized target cells. Toxicol Appl Pharmacol. 2009;239:306-19. • Konduru NV, Tyurina YY, Feng W, Basova LV, Belikova NA, Bayir H, Clark K, Rubin M, Stolz D, Vallhov H, Scheynius A, Witasp E, Fadeel B, Kichambare PD, Star A, Kisin ER, Murray AR, Shvedova AA, Kagan VE. Phosphatidylserine targets single-walled carbon nanotubes to professional phagocytes in vitro and in vivo. PLoS ONE 2009;4(2):e4398. • Allen BL, Kotchey GP, Chen Y, Yanamala NV, Klein- Seetharaman J, Kagan VE, Star A. Mechanistic investigations of horseradish peroxidase-catalyzed degradation of single-walled carbon nanotubes. J Am Chem Soc. 2009;131:17194-205. • Gwinn MR, Tran L. Risk management of nanomaterials. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2:130-137. • Fadeel B, Garcia-Bennett AE. Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev. 2010;62:362-374. • Shvedova AA, Kagan VE, Fadeel B. Close encounters of the small kind: adverse effects of man-made materials interfacing with the nano-cosmos of biological systems. Annu Rev Pharmacol Toxicol. 2010;50:63-88. • Kagan VE, Konduru NV, Feng W, Allen BL, Conroy J, Volkov Y, Vlasova II, Belikova NA, Yanamala N, Kapralov A, Tyurina YY, Shi J, Kisin ER, Murray AR, Franks J, Stolz D, Gou P, Klein-Seetharaman J, Fadeel B, Star A, Shvedova AA. Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation. Nat Nanotechnol. 2010;5:354-359. • Feliu N, Fadeel B. Nanotoxicology: no small matter. Nanoscale 2010;2:2514-2520. • Xia XR, Monteiro-Riviere NA, Riviere JE. An index for characterization of nanomaterials in biological systems. Nat Nanotechnol. 2010;5:671-5. • Krug HF, Wick P. Nanotoxicology: an interdisciplinary challenge. Angew Chem Int Ed Engl. 2011 Feb 7;50(6):1260- 78. • Kisin E, Murray A, Sargent LM, Lowry D, Chirila M, Siegrist KJ, Schwegler-Berry D, Leonard S, Castranova V, Fadeel B, Kagan VE, Shvedova AA. Genotoxicity of carbon nanofibers: are they potentially more or less dangerous than carbon nanotubes or asbestos? Toxicol Appl Pharmacol. 2011;252:1-10. 3 Directory Table 1 Directory of people involved in this project. • Kotchey GP, Allen BL, Vedala H, Yanamala N, Kapralov AA, Tyurina YY, Klein-Seetharaman J, Kagan VE, Star A. The enzymatic oxidation of graphene oxide. ACS NANO. 2011;5:2098-108. • Kunzmann A, Andersson B, Vogt C, Feliu N, Ye F, Gabrielsson S, Toprak M, Thurnherr T, Laurent S, Vahter M, Krug H, Muhammed M, Scheynius A, Fadeel B. Efficient internalization of silica-coated iron oxide nanoparticles of different sizes by primary human macrophages and dendritic cells. Toxicol Appl Pharmacol. 2011;253:81-93. • Tkach AV, Shurin GV, Shurin MR, Kisin ER, Murray AR, Young S-H, Star A, Fadeel B, Kagan VE, Shvedova AA. Direct effects of carbon nanotubes on dendritic cells induce immune suppression upon pulmonary exposure. ACS-NANO. 2011;5:5755-62. • Wilkinson K, Palmberg L, Witasp E, Kupczyk M, Feliu N, Gerde P, Fadeel B, Seisenbaeva G, Dahlén S-E, Kessler V. Solution engineered Pd-nanoparticles: model for health effect studies of automotive particulate pollution. ACS NANO. 2011;5:5755-62. • Tyurina YY, Kisin ER, Murray A, Tyurin VA, Kapralova VI, Spavero LJ, Amoscato AA, Samhan-Arias AK, Swedin L, Lahesmaa R, Fadeel B, Shvedova AA, Kagan VE. Global phospholipidomics analysis reveals selective pulmonary peroxidation profiles upon inhalation of single-walled carbon nanotubes. ACS NANO. 2011;5:7342-53. • Xiao L, Li J, Brougham DF, Fox EK, Feliu N, Bushmelev A, Schmidt A, Mertens N, Kiessling F, Fadeel B, Mathur S. Water-soluble superparamagnetic magnetite nanoparticles with biocompatible coating for enhanced magnetic resonance Imaging (MRI). ACS-NANO. 2011;5(8):6315-24. • Xia XR, Monteiro-Riviere NA, Mathur S, Oldenberg S, Fadeel B, Riviere JE. Mapping the surface adsorption forces of nanomaterials in biological systems. ACS-NANO. 2011;5:9074-81. • Shvedova AA, Kapralov O, Feng W, Kisin ER, Murray A, Mercer R, St Croix C, Lang M, Watkins S, Konduru N, Allen B, Conroy J, Mohamed BM, Meade AD, Volkov Y, Fadeel B, Kagan VE. Impaired clearance and enhanced pulmonary inflammatory/fibrotic response to carbon nanotubes in myeloperoxidase-deficient mice. PLoS ONE [in press]. First Name Last Name Affiliation Role in project Address E-mail Erika Witasp Karolinska Institutet Bengt Fadeel Karolinska Institutet Project Manager Nobels väg 13, SE-17177 Stockholm, Sweden Project Coordinator Nobels väg 13, SE-17177 Stockholm, Sweden erika.witasp@ki.se bengt.fadeel@ki.se 156 Compendium of Projects in the European NanoSafety Cluster
First Name Last Name Affiliation Role in project Address E-mail Valerian Kagan University of Pittsburgh Principal Investigator Bridgeside Point, 100 Technology Drive, Room 330, Pittsburgh, PA 15219-3130, USA Harald Krug EMPA Work Package Leader Lerchenfeldstrasse 5, CH-9014 St. Gallen, Switzerland Riitta Lahesmaa University of Turku Sanjay Mathur University of Cologne Nancy Monteiro-Riviere North Carolina State University Mamoun Muhammed Royal Institute of Technology Jim Riviere North Carolina State University Annika Scheynius Karolinska Institutet Work Package Leader Tykistökatu 6 B, FIN-20521 Turku, Finland Work Package Leader Lehrstuhl für Anorganische und Materialchemie Greinstraße 6, D- 50939 Koeln, Germany Principal Investigator 4700 Hillsborough St. Raleigh, N.C. 27606, USA Principal Investigator KTH - Electrum 229, Isafjordsgatan 22, SE - 164 40 Kista, Sweden Principal Investigator 4700 Hillsborough St. Raleigh, N.C. 27606, USA Principal Investigator Karolinska University Hospital Solna NanoSafetyCluster - Compendium 2012 kagan@pitt.edu harald.krug@empa.ch riitta.lahesmaa@btk.fi sanjay.mathur@uni-koeln.de nancy_monteiro@ncsu.edu mamoun@kth.se jim_riviere@ncsu.edu Compendium of Projects in the European NanoSafety Cluster 157 L2:04 SE- 171 76 Stockholm Sweden Anna Shvedova NIOSH Work Package Leader 1095 Willow dale Road Morgantown, WV 26505-2888, USA Alexander Star University of Pittsburgh Maria Strømme Uppsala University Lang Tran Institute of Occupational Medicine 4 Copyright Principal Investigator 112 Eberly Hall, 219 Parkman Avenue, Pittsburgh, PA 15260, USA Principal Investigator Uppsala University, P O Box 534, SE-751 21 Uppsala, Sweden Work Package Leader Institute of Occupational Medicine, Research Avenue North, Riccarton, Edinburgh, EH14 4AP, UK annika.scheynius@ki.se ats1@cdc.gov astar@pitt.edu maria.stromme@angstrom.uu.se lang.tran@iom-world.org © 2012, Karolinska Institutet, Stockholm, Sweden on behalf of the NANOMMUNE consortium. NANOMMUNE is a Collaborative Research Project under the European Commission's 7th Framework Programme. This is an Open Access document distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Under the following conditions: Attribution. • NANOMMUNE and the European Commission's 7th Framework Programme must be given credit, but not in any way that suggests that they endorse you or your use of the work; • For any reuse or distribution, you must make clear to others the license terms of this work. The best way to do this is with a link to this web page: http://creativecommons.org/licenses/by/3.0. Statutory fair use and other rights are in no way affected by the above.
Page 1:
Compendium of Projects in the Europ
Page 5 and 6:
EDITED BY Michael Riediker, PD Dr.s
Page 7 and 8:
CONTENTS NanoSafetyCluster - Compen
Page 9 and 10:
Project Acronym ENNSATOX ENPRA EURO
Page 11 and 12:
Foreword NanoSafetyCluster - Compen
Page 13 and 14:
ENNSATOX ENgineered Nanoparticle Im
Page 15 and 16:
The biological membrane and its dep
Page 17 and 18:
distinguishes between the interacti
Page 19 and 20:
Figure 10. Schematic representation
Page 21 and 22:
WP5: • Permeability of NPs in hyd
Page 23 and 24:
NanoSafetyCluster - Compendium 2012
Page 25 and 26:
ENPRA RISK ASSESSMENT OF ENGINEERED
Page 27 and 28:
vitro findings with in vivo models;
Page 29 and 30:
protocols with real biological samp
Page 31 and 32:
and it was organised in the frame o
Page 33 and 34:
First Name Last Name Affiliation Ad
Page 35 and 36:
Page 37 and 38:
EURO-NanoTox European Center for Na
Page 39 and 40:
silver nanoparticles, iron nanopart
Page 41 and 42:
The core functions of the Center, h
Page 43 and 44:
8 Directory Table 1 Directory of pe
Page 45 and 46:
HINAMOX Health Impact of Engineered
Page 47 and 48:
High Resolution Electron Microscopy
Page 49 and 50:
integrated risk assessment. Integra
Page 51 and 52:
powders: What is the difference in
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
InLiveTox Intestinal, Liver and End
Page 59 and 60:
- to develop and validate a novel m
Page 61 and 62:
environments, IEEE Industrial Elect
Page 63 and 64:
INSTANT Innovative Sensor for the f
Page 65 and 66:
complementary research which will l
Page 67 and 68:
7 Copyright NanoSafetyCluster - Com
Page 69 and 70:
ITS-NANO Intelligent testing strate
Page 71 and 72:
approach to conveying the appropria
Page 73 and 74:
in the discussion. The integration
Page 75 and 76:
MARINA MANAGING RISKS of NANOMATERI
Page 77 and 78:
for risk analysis, these tools need
Page 79 and 80:
environmental ENM toxicity, but tox
Page 81 and 82:
propose it as a Method Validation F
Page 83 and 84:
and SiO2-NM200 and NM203, and a SiO
Page 85 and 86:
ModNanoTox Modelling nanoparticle t
Page 87 and 88:
3) To model environmental exposure
Page 89 and 90:
Nanodetector European Network on th
Page 91 and 92:
measurement interval. Measurements
Page 93 and 94:
5 Directory Table 1 Directory of pe
Page 95 and 96:
NANODEVICE Novel Concepts, Methods,
Page 97 and 98:
ENP in order to be sure of their sa
Page 99 and 100:
4.3 Exploring the association betwe
Page 101 and 102:
Page 103 and 104:
NanoFATE Nanoparticle Fate Assessme
Page 105 and 106:
or proteins associated with particu
Page 107 and 108:
sludge. Information on rates of slu
Page 109 and 110:
The exposures to be conducted will
Page 111:
NanoFATE progression beyond the “
Page 114 and 115:
Page 116 and 117: NanoSafetyCluster - Compendium 2012
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
NanoSafetyCluster ‐ Compendium 20
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288:
show all

Timing, hosts and locations of (grouped) events of NanoImpactNet

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?